STANDARD BIOTOOLS INC. 8-K

What Happened
Standard BioTools Inc. (NASDAQ: LAB) filed an 8-K on April 24, 2026, disclosing that Nasdaq’s Listing Qualifications Department notified the company it did not meet the $1.00 minimum bid price required under Nasdaq Listing Rule 5450(a)(1) after 30 consecutive business days below that threshold. Under Nasdaq Listing Rule 5810(c)(3)(A) this triggered an automatic 180-calendar-day compliance period, giving the company until October 19, 2026, to regain compliance. The Notice does not have an immediate effect on the listing or trading of the company’s common stock (it continues to trade as “LAB”) and does not affect the company’s business operations or SEC reporting obligations.

Key Details

• Filing date: April 24, 2026 (8-K Item 3.01).
• Compliance window: 180 calendar days from the Notice; deadline to cure is October 19, 2026.
• Cure requirement: regain a closing bid of at least $1.00 for a minimum of 10 consecutive business days to be compliant.
• Possible remedies: if other listing standards are met, the company may apply for an additional 180‑day period by transferring to The Nasdaq Capital Market and providing written notice (options may include a reverse stock split and payment of Nasdaq application fees). Signatory: Alex Kim, Chief Financial Officer.

Why It Matters
For investors, this notice signals a risk that the company could face Nasdaq delisting proceedings if it does not meet the minimum bid-price requirement by the October 19, 2026 deadline. Delisting (or the threat of it) can reduce stock liquidity, limit trading venues, and make it harder for the company to raise capital. However, trading of LAB remains uninterrupted for now and the company has stated it intends to work to regain compliance; there is no assurance it will succeed.